Insider Trading & Ownership of GSK plc

Location
London
Summary
The estimated value of insider holdings of GSK plc is at least $446,013,072 dollars as of 15 Dec 2025. GSK plc is the 10%+ Owner of Wave Life Sciences Ltd. and owns shares of Wave Life Sciences Ltd. (WVE) stock worth about $346.67M. GSK plc is the 10%+ Owner of Lyell Immunopharma, Inc. and owns shares of Lyell Immunopharma, Inc. (LYEL) stock worth about $68.98M. GSK plc is the 10%+ Owner of CVRx, Inc. and owns shares of CVRx, Inc. (CVRX) stock worth about $18.7M. GSK plc is the 10%+ Owner of Spero Therapeutics, Inc. and owns shares of Spero Therapeutics, Inc. (SPRO) stock worth about $11.67M.
Signature
/s/ Victoria Whyte, Authorized Signatory, GSK plc
All Insider Reports
All Insider Reports

Follow Filing Activity

Follow GSK plc and return when a new Insider Trading filing appears.

This tracks SEC filing changes for this page using existing product update flows.

Sponsored

Quick Takeaways

  • GSK plc has 7 issuer positions tracked on this page.
  • Estimated disclosed ownership value: $446,013,072.
  • Recent insider filing activity is available below.

What Changed

  • Largest disclosed position: Wave Life Sciences Ltd. ($346,668,129).
  • Past-year value change for that position: +$27,930,000.

Why This Matters

  • This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
  • You can cross-check role, issuer, and filing chronology directly against the SEC source.

Official SEC Source

Filed on Form 4

Insider ownership context is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Ownership of GSK plc

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
WVE Wave Life Sciences Ltd. 10%+ Owner $346,668,129 +$27,930,000 +8.8% 11 Dec 2025
LYEL Lyell Immunopharma, Inc. 10%+ Owner $68,977,271 21 Jun 2021
CVRX CVRx, Inc. 10%+ Owner $18,695,602 02 Jul 2021
SPRO Spero Therapeutics, Inc. 10%+ Owner $11,672,070 07 Nov 2022
MEHCQ 23andMe Holding Co. 10%+ Owner 16 Jun 2021
INVA Innoviva, Inc. 10%+ Owner 20 May 2021
TBPH Theravance Biopharma, Inc. Former 10% Owner 16 Sep 2022

Insider Transactions Reported by GSK plc:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.